BioSpace News Archive

Hope Medicine Inc. has recently announced that U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for phase II study to evaluate HMI-115, a first-in-class monoclonal antibody drug in treating androgen alopecia.

NeuroSigma, Inc., a bioelectronic medical device company, and Ignis Therapeutics, a life science company focusing on the central nervous system therapies, jointly announced that Ignis Therapeutics has acquired the exclusive license in China of NeuroSigma’s Monarch eTNS System® to treat attention deficit hyperactivity disorder.